Immuneering Corp — Director's Dealing 2022

Feb 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2022-02-10

Reporting Person: Zeskind Benjamin J. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-10	Stock Option	$9.66	A	156485	Acquired	2032-02-09	Class A Common Stock (156485)	Direct
2022-02-10	Stock Option	$10.63	A	45615	Acquired	2027-02-09	Class A Common Stock (45615)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026.

F2: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026.